Viatris Expects First “Interchangeable” Designation in July 2021 For Insulin Products

Viatris announced during its Q1 2021 earnings call that its insulin glargine and insulin aspart products are both on track to be approved by the FDA as interchangeable by July 2021. These are proposed biosimilars of Sanofi’s LANTUS and Novo Nordisk’s NOVOLOG/NOVORAPID products, respectively.  If approved, Viatris’s insulin products would be the first biosimilars to receive interchangeable designations by the FDA.

Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.